The FAP+ CAF subset in bladder cancer: A key driver of cancer cell stemness and a promising target for FAPI therapy

Meiqian Li; Shikun Wang; Hua Xiao; Rong Hu; Yueyun Xie

doi:10.1002/ctd2.70179

Clinical and Translational Discovery ›› 2026, Vol. 6 ›› Issue (4) :e70179 DOI: 10.1002/ctd2.70179

INVITED LETTER

The FAP⁺ CAF subset in bladder cancer: A key driver of cancer cell stemness and a promising target for FAPI therapy

Author information +

History +

PDF (535KB)

Cite this article

Download citation ▾

Meiqian Li, Shikun Wang, Hua Xiao, Rong Hu, Yueyun Xie. The FAP⁺ CAF subset in bladder cancer: A key driver of cancer cell stemness and a promising target for FAPI therapy. Clinical and Translational Discovery, 2026, 6 (4) : e70179 DOI:10.1002/ctd2.70179

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics. CA Cancer J Clin. 2025; 75(1): 10-45.

[2]	Wu J, Liu B, Chen S, Xin J, Wang M. Stromal FAP+ cancer associated fibroblasts orchestrate a pro-tumorigenic niche with malignant proliferative stemness and cancer progression. Clin Transl Med. 2026; 16(5): e70688.

[3]	Zhuang J, Shen L, Li M, et al. Cancer-associated fibroblast-derived miR-146a-5p generates a niche that promotes bladder cancer stemness and chemoresistance. Cancer Res. 2023; 83(10): 1611-1627.

[4]	Zhou Z, Chen Y, Wang Z, et al. Characterization of cancer-related fibroblasts in bladder cancer and construction of CAFs-based bladder cancer classification: insights from single-cell and multi-omics analysis. Front Immunol. 2025; 16: 1580986.

[5]	Caramelo B, Zagorac S, Corral S, Marqués M, Real FX. Cancer-associated fibroblasts in bladder cancer: origin, biology, and therapeutic opportunities. Eur Urol Oncol. 2023; 6(4): 366-375.

[6]	Muilwijk T, Baekelandt L, Akand M, et al. Fibroblast activation protein-α and the immune landscape: unraveling T1 non-muscle-invasive bladder cancer progression. Eur Urol Open Sci. 2024; 66: 67-74.

[7]	Ping Q, Wang C, Cheng X, et al. TGF-β1 dominates stromal fibroblast-mediated EMT via the FAP/VCAN axis in bladder cancer cells. J Transl Med. 2023; 21(1): 475.

[8]	Filippi L, Mass ACL, Arslan E, Alçın G, Guglielmo P, Evangelista L. Is There a Role of FAPI Pet in Renal and Bladder Cancer?. Semin Nucl Med. 2026; 56(2): 173-187.

Rights & permissions

2026 The Author(s). Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.